MET and renal carcinoma: D’Amico et al. highlighted the roles of cancer stem cells expressing c-Met in renal cancer bone metastasis, and showed that the c-Met inhibitor JNJ-38877605 inhibits osteoclast activation in a preclinical NOD/SCID mouse model [49].